It has long been observed that certain clinical conditions, including multiple sclerosis (MS), improve during pregnancy, a period during which the maternal immune system undergoes an altered state, providing a non-immunogenic environment for the fetus that enables implantation, differentiation and growth. 

At BioIncept®, we are leveraging our proprietary research and understanding of the molecular drivers of the altered maternal immune state to develop diagnostic and therapeutic products for patients in need.

Founded as a research organization

• understanding altered maternal immunity
• distinguished network of research collaborators
• explored breadth of how PreImplantation Factor (PIF) could help patients in need
• robust global patent estate developed
• first-in-human phase 1 clinical safety study successfully completed at University of Miami, Schiff Liver Center

Evolution to commercially oriented product development

Today, a clinical-stage company based in New York developing therapeutics and diagnostics that meet commercial criteria, e.g.:

• proof-of-concept established or possible near-term
• commercial market need for innovation
• clear development path
• corporate development impact

Our lead therapeutic focus, MS, is a devastating, progressive disease affecting one million patients in the US alone⁽¹⁾ where treatment options remain inadequate despite generating annual global revenues of US$ 23 billion^(2).

We were awarded orphan drug designations including in prevention of graft-vs-host disease and acute radiation syndrome; both programs are supported by the US government attracting non-dilutive funding of more than US$ 10 million across various grants.